Views: 1778 Author: Unibest Industrial Publish Time: 2025-12-01 Origin: Site
Last Updated: 2025-12-01
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB410 | HER2 | Metastatic breast cancer | ||||||
| UB409 | HER2 | HER2-positive breast cancer | ||||||
| UB391 | Her2/Her2 | Breast cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer | ||||||
| UB390 | ROR1 | Solid tumour; Haematologic malignancy | ||||||
| UB044 | Microtubule (ADC payload) | HER2-negative breast cancer; HER2-positive gastric cancer | ||||||
| UB320 | ROR1; DNA Topoisomerase I | Diffuse large B-cell lymphoma | ||||||
| UB322 | MUC17; DNA Topoisomerase I | Solid tumour | ||||||
| UB323 | FGFR2b; DNA Topoisomerase I | Solid tumour | ||||||
| UB319 | ROR1; DNA Topoisomerase I | Solid tumour | ||||||
| UB318 | ROR1; DNA Topoisomerase I | Mantle cell lymphoma; Diffuse large B-cell lymphoma; Classical Hodgkin's disease | ||||||
| UB424 | BCMA | Multiple myeloma | ||||||
| UB321 | CDH17; DNA Topoisomerase I | Gastrointestinal cancer | ||||||
| UB394 | GPC3 | Solid tumour | ||||||
| UB392 | CLDN6 | Solid tumour | ||||||
| UB393 | ITGB6 | Solid tumour | ||||||
| UB022 | HER2/Trop2 | Breast cancer; Cervical cancer; Gastric cancer | ||||||
| UB032 | Nectin-4/Trop2 | Bladder cancer; Cervical cancer; Lung cancer | ||||||
| UB031 | cMet/HER2 | Pancreatic cancer; Lung cancer; Gastrointestinal cancer; Renal cancer | ||||||
| UB127 | EGFR; cMet | Lung cancer | ||||||
| UB126 | ADAM9 | Gastrointestinal cancer | ||||||
| UB191 | TROP2 BsAb + Dual-payload | Pancreatic cancer | ||||||
| UB138 | Undisclosed (BsAb+Dual-payload) | Solid tumour | ||||||
| UB137 | Undisclosed (mAb+Dual-payload) | Solid tumour | ||||||
| UB136 | BsAb + Dual-payload | Solid tumour | ||||||
| UB431 | DLL3 BsAb + Dual-payload | Small cell lung cancer; Neuroendocrine tumour | ||||||
| UB189 | B7H3 BsAb + Dual-payload | Small cell lung cancer | ||||||
| UB190 | B7H3 Bi-functional+ Dual-payload | Prostate cancer | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB493 | Non-small cell lung cancer; Colorectal cancer metastatic | |||||||
| UB186 | EGFR | Colorectal cancer | About | |||||
| UB187 | PD1 | Recurrent thymic carcinoma; Metastatic thymic carcinoma | ||||||
| UB302 | VEGF-A | Neovascular age-related macular degeneration | ||||||
| UB335 | IL-6R | Rheumatoid arthritis | ||||||
| UB336 | IL-6R | Idiopathic multicentric Castleman disease | ||||||
| UB331 | IL-4Rα | Atopic dermatitis | About | |||||
| UB330 | IL-4Rα | Prurigo nodularis | About | |||||
| UB426 | IL4 | Atopic dermatitis; Prurigo nodularis; Asthma | ||||||
| UB396 | EGFR/cMet | Solid tumour | ||||||
| UB014 | EGFR; CD3 | Breast cancer metastatic; Gastric cancer | About | |||||
| UB408 | BCMA/CD3 | Multiple myeloma; Primary amyloidosis | ||||||
| UB013 | LAG3 | Solid tumour; Lymphoma; Autoimmune disorder | About | |||||
| UB017 | IL-12 prodrug | Solid tumour | About | |||||
| UB149 | Aβ | Alzheimer's disease | ||||||
| UB385 | IL36R | Autoimmune disorder | ||||||
| UB423 | PDL1 x VEGF x TGFb | Solid tumour | ||||||
| UB015 | EGFR; CD3 (enzyme-controlled) | Solid tumour | About | |||||
| UB019 | GPC3; CD3 | Hepatocellular carcinoma | About | |||||
| UB427 | OX40L x TNFα; OX40L | Atopic dermatitis; Hidradenitis suppurativa; Asthma | ||||||
| UB333 | (BsAb) | IgA nephropathy | ||||||
| UB332 | (BsAb) | Inflammatory bowel disease; Psoriasis; Psoriatic arthritis | ||||||
| UB266 | CD38 | Multiple myeloma (MM); Multiple myeloma | ||||||
| UB340 | TL1A | Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Systemic sclerosis | ||||||
| UB343 | TL1A; IL-6R | Inflammatory bowel disease; Thyroid eye disease | ||||||
| UB341 | TL1A; IL-23p19 | Inflammatory bowel disease; Psoriasis | ||||||
| UB342 | TL1A; TNF-α | Inflammatory bowel disease; Rheumatoid arthritis | ||||||
| UB345 | IL-6R; TNF-α | Uveitis; Neuromyelitis optica spectrum disorder; Dental caries | ||||||
| UB344 | IL-6R; IL-23p19 | Rheumatoid arthritis; Thyroid eye disease; Chronic kidney disease; Atherosclerotic cardiovascular disease | ||||||
| UB267 | CD38 | Multiple myeloma | ||||||
| UB018 | RORI; CD3 | Lymphoma; Breast cancer | ||||||
| UB023 | PD-L1; VEGF | Lung cancer; Breast cancer | ||||||
| UB041 | HERV-K Env-TM | Malignant neoplasm | ||||||
| UB020 | PD-1/IL-15 cytokine antibody conjudgate | Solid tumour | About | |||||
| UB377 | ActRIIA/B | Obesity | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB425 | CD19 | Diffuse large B-cell lymphoma; Mantle cell lymphoma; Acute lymphoblastic leukaemia | ||||||
| UB098 | HBV | Hepatocellular carcinoma | About | |||||
| UB038 | TGFβ1; COX-2 (siRNA) | Non-melanoma skin cancer | About | |||||
| UB084 | (Oncolytic virus) | Head and neck squamous cell carcinoma; Lung cancer; Ovarian cancer; Sarcoma; Triple negative breast cancer | About | |||||
| UB039 | TGFβ1; COX-2 (siRNA) | Localised adiposity | About | |||||
| UB145 | Factor XI (siRNA) | Anticoagulant therapy; Stroke | ||||||
| UB144 | (siRNA) | Solid tumour | ||||||
| UB139 | PCSK9 (siRNA) | Hypercholesterolaemia | ||||||
| UB354 | Varicella zoster virus infection | |||||||
| UB099 | HBV | Cholangiocarcinoma | About | |||||
| UB499 | Malignant neoplasm | |||||||
| UB494 | CD7 | T-cell acute lymphoblastic leukaemia; Lymphoblastic lymphoma | ||||||
| UB496 | Neoplasm malignant | |||||||
| UB140 | PCSK9 (siRNA) | Hypercholesterolaemia | ||||||
| UB101 | HPV | Cervical cancer; Head and neck cancer | About | |||||
| UB100 | HBV | Chronic hepatitis B | About | |||||
| UB085 | (Oncolytic virus) | Head and neck squamous cell carcinoma; Lung cancer; Ovarian cancer; Sarcoma; Triple negative breast cancer | About | |||||
| UB495 | Neoplasm malignant | |||||||
| UB355 | Tuberculosis | |||||||
| UB356 | Malignant neoplasm | |||||||
| UB095 | (siRNA) | Nephrotic syndrome | ||||||
| UB089 | IL4R (siRNA) | Atopic dermatitis | ||||||
| UB092 | (siRNA) | Age-related macular degeneration | ||||||
| UB090 | Calcineurin/Fn14 (siRNA) | Transplantation; Autoimmune disorder | ||||||
| UB146 | ApoC3 (siRNA) | Hypertriglyceridaemia | ||||||
| UB498 | Malignant neoplasm; Infection | |||||||
| UB097 | (siRNA) | Melanoma | ||||||
| UB102 | EBV | Solid tumour | About | |||||
| UB096 | SGLT2 (siRNA) | Type 2 diabetes mellitus; Gout | ||||||
| UB103 | (iPSC) | Solid tumour | About | |||||
| UB418 | Retina | Retinal degeneration | ||||||
| UB091 | Glucosylceramide synthase (siRNA) | Gaucher's disease; Fabry's disease | ||||||
| UB093 | Renin / AGT | Hypertension | ||||||
| UB094 | FcRn (siRNA) | Myasthenia gravis | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB350 | GLP-1; GLP-2 | Obesity; Type 2 diabetes mellitus | ||||||
| UB325 | FGF21R; GCGR; GLP-1 R | Metabolic dysfunction-associated fatty liver disease | About | |||||
| UB326 | FGF21R; GCGR; GLP-1 R | Hypertriglyceridaemia | About | |||||
| UB421 | GLP-1 x GCG x FGF21 | Metabolic dysfunction-associated steatohepatitis; Symptomatic Human Thyroidal Group | ||||||
| UB337 | CD80; CD86 | Rheumatoid arthritis; Systemic lupus erythematosus; Graft versus host disease | ||||||
| UB329 | CLDN18.2 | Solid tumour | About | |||||
| UB328 | PDL1; VEGF; TGFβ | Gastrointestinal cancer | About | |||||
| UB327 | PDL1; VEGF; TGFβ | Non-small cell lung cancer | About | |||||
| UB338 | IL-1R1 | Cryopyrin-associated periodic syndromes; Gouty arthritis | ||||||
| UB352 | αActRII; αMyostatin | Obesity | ||||||
| UB351 | GLP-1; GLP-2 | Obesity | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB011 | GLP-1 R | Diabetes mellitus | About | |||||
| UB430 | Insulin receptor | Diabetes | ||||||
| UB080 | GLP-1 | Obesity | About | |||||
| UB298 | Insulin receptor | Type 2 diabetes mellitus | ||||||
| UB045 | GLP-1 | Type 2 diabetes mellitus | About | |||||
| UB081 | GLP-1 | Nonalcoholic steatohepatitis | About | |||||
| UB316 | GLP-1; GIP | Diabetes mellitus | ||||||
| UB315 | GLP-1; GIP | Obesity; Overweight | ||||||
| UB012 | GLP-1 R | Obesity | About | |||||
| UB411 | Functional fragment of Thymosin β4 | Corneal epithelial defect; Pterygium; Neurotrophic keratitis | ||||||
| UB047 | GLP-1; GCG | Obesity | About | |||||
| UB285 | Tumor neuantigens | Pancreatic cancer | About | |||||
| UB048 | GLP-1; GCG | Nonalcoholic steatohepatitis | About | |||||
| UB049 | ÎĽ opioid receptor | Opioid-induced constipation | About | |||||
| UB317 | GLP-1; GIP | Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obstructive sleep apnoea syndrome; Cardiac failure with preserved ejection fraction | ||||||
| UB046 | GLP-1 | Type 2 diabetes mellitus | About | |||||
| UB050 | GCGR | Congenital hyperinsulinism | About | |||||
| UB263 | GLP-1 R | Type 2 diabetes mellitus | About | |||||
| UB051 | GLP-1; GIP | Type 2 diabetes mellitus; Obesity; Nonalcoholic steatohepatitis | About | |||||
| UB052 | GLP-1R; GIPR; GCGR | Type 2 diabetes mellitus; Obesity; Metabolic dysfunction-associated steatohepatitis | About | |||||
| UB104 | GLP-1 (Oromucosal) | Diabetes mellitus; Obesity | ||||||
| UB010 | GLP-1 R | Diabetes mellitus | About | |||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB432 | TLR9 | Peritoneal carcinomatosis; Solid tumour | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB434 | Ischaemic stroke | |||||||
| UB433 | Amyotrophic lateral sclerosis | |||||||
| UB437 | Multiple system atrophy; CADASIL | |||||||
| UB436 | Traumatic brain injury | |||||||
| UB435 | Alzheimer's disease | |||||||
| UB438 | Amyotrophic lateral sclerosis | |||||||
| UB412 | Diabetic macular oedema; Exudative age-related macular degeneration | |||||||
| UB439 | Autism spectrum disorder | |||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB339 | Treg | Inflammatory bowel disease; Amyotrophic lateral sclerosis; Systemic lupus erythematosus | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB202 | Lanosterol 14-alpha demethylase | Invasive aspergillosis; Mucormycosis | ANDA | |||||
| UB422 | Neuroprotective | Cerebrovascular accident | ||||||
| UB082 | F protein (RSV) | Respiratory syncytial virus infection | About | |||||
| UB360 | P2Y12R | Peripheral arterial disease | About | |||||
| UB395 | CDK2/4/6 | Breast cancer metastatic; Liposarcoma; Lung cancer metastatic | ||||||
| UB314 | EGFR (L858R) | Non-small cell lung cancer | ||||||
| UB068 | JAK1 (oral) | Ankylosing spondylitis | About | |||||
| UB312 | GLP-1 (oral) | Obesity; Overweight | ||||||
| UB309 | JAK1; JAK2 | Vitiligo | ||||||
| UB313 | GLP-1 (oral) | Diabetes mellitus | ||||||
| UB384 | PDE3/4 | Chronic obstructive pulmonary disease | ||||||
| UB353 | SYK inhibitor | Immune thrombocytopenia | ||||||
| UB361 | JAK1 (oral) | Atopic dermatitis | About | |||||
| UB063 | HBV Caspid | Chronic hepatitis B | About | |||||
| UB428 | PDE4 | Psoriasis; Atopic dermatitis | ||||||
| UB429 | Steroid + VD | Psoriasis | ||||||
| UB062 | KCNQ2/3 | Epilepsy | About | |||||
| UB347 | Core Protein CpAM | Hepatitis B | ||||||
| UB348 | Surface Antigen HBsAg | Hepatitis B | ||||||
| UB386 | AT2R | Post-stroke pain | ||||||
| UB310 | JAK1; JAK2 | Prurigo nodularis | ||||||
| UB362 | JAK1 (oral) | Vitiligo | About | |||||
| UB067 | JAK1 (Gel) | Atopic dermatitis | About | |||||
| UB042 | 5-HT; DA | Autism spectrum disorder; Atrial septal defect; Acute stress disorder | About | |||||
| UB024 | KV1.3 (Topical) | Atopic dermatitis | About | |||||
| UB027 | mTORC2 | Neuroendocrine tumour; Lung cancer; Breast cancer | ||||||
| UB064 | TEAD | Malignant neoplasm | About | |||||
| UB387 | BTK | Haematological malignancy | ||||||
| UB397 | EGFR | Lung cancer | ||||||
| UB388 | AR | Metastatic castration-resistant prostate cancer | ||||||
| UB364 | JAK1 (oral) | Rheumatoid arthritis | About | |||||
| UB028 | FXIa | Thrombus | ||||||
| UB026 | PI3K-Akt-mTOR pathway | Malignant melanoma; Oesophageal cancer; Colorectal cancer | ||||||
| UB176 | KV1.3 (Topical) | Psoriasis | About | |||||
| UB147 | Keratin; Plasmin | |||||||
| UB083 | F protein (RSV) | Respiratory syncytial virus infection prophylaxis | About | |||||
| UB349 | ASK-1 | Nonalcoholic steatohepatitis; Hepatic fibrosis | ||||||
| UB363 | JAK1 (oral) | Inflammatory bowel disease | About | |||||
| UB069 | RIPK1 | Peripheral arterial disease; Primary biliary cholangitis | About | |||||
| UB497 | Cervical intraepithelial neoplasia | |||||||
| UB509 | IDH1 mutation | Low grade glioma; Cholangiocarcinoma; Chondrosarcoma | ||||||
| UB365 | TRKA (Gel) | Skin inflammation; Pruritus | About | |||||
| UB148 | Androgen receptor | |||||||
| UB029 | KV1.3 (Oral) | Inflammatory bowel disease | About | |||||
| UB030 | cMyc pathway | Gynaecological neoplasm | ||||||
| UB177 | KV1.3 (Oral) | Atopic dermatitis | About | |||||
| UB284 | AChE | Myasthenia gravis | ||||||
| UB404 | MENIN | Haematological malignancy | ||||||
| UB398 | Pan KRAS | Solid tumour | ||||||
| UB376 | GLP-1R | Obesity | ||||||
| UB366 | TRKA/B/C | Solid tumour | About | |||||
| UB389 | ER | Breast cancer | ||||||
| UB401 | USP1 | Solid tumour | ||||||
| UB400 | PARP1 | Solid tumour; Brain metastases | ||||||
| UB125 | GABAA Receptor | Epilepsy | ||||||
| UB183 | Ion channel inhibitor | Diabetic nephropathy | About | |||||
| UB178 | KV1.3 (Topical) | Alopecia | About | |||||
| UB179 | GPCR | Diabetic retinopathy; Age-related macular degeneration | About | |||||
| UB065 | P2Y12R | Acute coronary syndrome | About | |||||
| UB066 | P2Y12R | Ischaemic stroke | About | |||||
| UB070 | pan-RAS (on) | Solid tumour | About | |||||
| UB043 | Agmatinase; Imidazoline Rc; NMDA Rc | Atrial septal defect; Autism spectrum disorder; Acute stress disorder | About | |||||
| UB040 | Multiple targets; immunostimulants | Malignant neoplasm | ||||||
| UB182 | Ion channel inhibitor | Pruritus | About | |||||
| UB180 | GPCR | Ocular inflammation | About | |||||
| UB181 | GPCR | Chronic obstructive pulmonary disease | About | |||||
| UB413 | Retinoblastoma | |||||||
| UB367 | IL-17 | Psoriasis | ||||||
| UB369 | ER-PROTAC | Breast cancer | ||||||
| UB368 | BTK-PROTAC | Systemic lupus erythematosus; Atopic dermatitis | ||||||
| UB371 | MAT2A | Solid tumour | ||||||
| UB370 | ATM | Solid tumour | ||||||
| UB372 | WRN | Solid tumour | ||||||
| UB380 | GIPR | Diabetes mellitus | ||||||
| UB381 | STAT6 | Autoimmune disorder; Respiratory disorder | ||||||
| UB373 | Inflammatory bowel disease | |||||||
| UB375 | Weight decreased | |||||||
| UB374 | Diabetes mellitus; Obesity | |||||||
| UB399 | Pan RAS | Solid tumour | ||||||
| UB406 | KEAP1 | Solid tumour | ||||||
| UB402 | PRMT5 | Solid tumour | ||||||
| UB407 | WFS1 | Solid tumour | ||||||
| UB405 | BTK | Chronic lymphocytic leukaemia; Small lymphocytic lymphoma; Diffuse large B-cell lymphoma | ||||||
| UB403 | POLQ | Solid tumour | ||||||
| UB383 | VAV1 | Autoimmune disorder | ||||||
| UB382 | NEK7-MGD | Autoimmune disorder | ||||||
| UB378 | ActRIIB | Obesity | ||||||
| UB379 | AMYR | Obesity; Diabetes mellitus | ||||||
| Code | Target | Indication | Preclinical | Ph I | Ph II | Ph III | NDA/BLA | Detail |
|---|---|---|---|---|---|---|---|---|
| UB025 | cMyc | Pancreatic cancer | ||||||
| UB324 | HPK-1 | Solid tumour | ||||||